Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

Ahmad Basil Nasir, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade · 2026

Read Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study by Ahmad Basil Nasir, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356138.txt.

Description

Ahmad Basil Nasir and colleagues mined American electronic health records for more than one and a half million adults with type 2 diabetes. They asked whether the diabetes drug a person takes tracks with later cognitive decline. Their 2026 retrospective study matched patients across five regimens, with metformin alone as the yardstick. It followed diagnoses of mild cognitive disorder, Alzheimer's disease, and vascular dementia over up to fourteen years.

Adding a GLP-1 drug to metformin was linked to roughly half the risk of vascular dementia and Alzheimer's. It was also linked to a lower rate of mild impairment. Adding an SGLT-2 drug cut vascular dementia only. Insulin alone looked worst on every outcome, likely reflecting more severe disease. The authors stress records show association, not proof.

Catalog record

CREATORAhmad Basil Nasir, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31973
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0356138

Browse the full library · About the Tower of Babel